Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-BRIGHT: AI-Enhanced CDK4/6 Inhibitor Rechallenge in HR+ HER2- Advanced Breast Cancer
NCT07227233Phase 2Recruiting
- Sponsor
- University of California, San Diego
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by University of California, San Diego. Primary endpoint: Progression-Free Survival at 6 months. Started Mar 2026; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07227233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227233.